Zheng Yifeng, Zhong Guoqiang, He Chengcheng, Li Mingsong
Department of Gastroenterology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Front Oncol. 2023 Aug 17;13:1222932. doi: 10.3389/fonc.2023.1222932. eCollection 2023.
RNA splicing is the process of forming mature mRNA, which is an essential phase necessary for gene expression and controls many aspects of cell proliferation, survival, and differentiation. Abnormal gene-splicing events are closely related to the development of tumors, and the generation of oncogenic isoform in splicing can promote tumor progression. As a main process of tumor-specific splicing variants, alternative splicing (AS) can promote tumor progression by increasing the production of oncogenic splicing isoforms and/or reducing the production of normal splicing isoforms. This is the focus of current research on the regulation of aberrant tumor splicing. So far, AS has been found to be associated with various aspects of tumor biology, including cell proliferation and invasion, resistance to apoptosis, and sensitivity to different chemotherapeutic drugs. This article will review the abnormal splicing events in colorectal cancer (CRC), especially the tumor-associated splicing variants arising from AS, aiming to offer an insight into CRC-targeted splicing therapy.
RNA剪接是形成成熟mRNA的过程，这是基因表达所必需的一个重要阶段，并且控制着细胞增殖、存活和分化的许多方面。异常的基因剪接事件与肿瘤的发生密切相关，剪接过程中致癌异构体的产生可促进肿瘤进展。作为肿瘤特异性剪接变体的主要过程，可变剪接（AS）可通过增加致癌剪接异构体的产生和/或减少正常剪接异构体的产生来促进肿瘤进展。这是当前关于异常肿瘤剪接调控研究的重点。到目前为止，已发现AS与肿瘤生物学的各个方面相关，包括细胞增殖和侵袭、抗凋亡能力以及对不同化疗药物的敏感性。本文将综述结直肠癌（CRC）中的异常剪接事件，特别是由AS产生的肿瘤相关剪接变体，旨在深入了解针对CRC的剪接治疗。
